These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17514187)

  • 1. The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder.
    Sheehan DV; Sheehan KH; Raj BA
    Psychopharmacol Bull; 2007; 40(2):63-81. PubMed ID: 17514187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics.
    Sheehan DV; Raj AB; Harnett-Sheehan K; Dorotheo J; Sheehan MF; Trehan R; Knapp E; Swiontek A; Coleman B
    Anxiety; 1996; 2(1):40-6. PubMed ID: 9160598
    [No Abstract]   [Full Text] [Related]  

  • 3. A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder.
    Pecknold J; Luthe L; Munjack D; Alexander P
    J Clin Psychopharmacol; 1994 Oct; 14(5):314-21. PubMed ID: 7806686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers.
    Glue P; Fang A; Gandelman K; Klee B
    Am J Ther; 2006; 13(5):418-22. PubMed ID: 16988537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
    Lydiard RB; Lesser IM; Ballenger JC; Rubin RT; Laraia M; DuPont R
    J Clin Psychopharmacol; 1992 Apr; 12(2):96-103. PubMed ID: 1573046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
    Pols H; Verburg K; Hauzer R; Meijer J; Griez E
    Biol Psychiatry; 1996 Nov; 40(9):913-7. PubMed ID: 8896779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.
    Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
    J Clin Psychopharmacol; 2006 Oct; 26(5):519-23. PubMed ID: 16974197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam.
    Klein E
    J Clin Psychiatry; 2002; 63 Suppl 14():27-33. PubMed ID: 12562116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical use of sustained release of alprazolam: A naturalistic study].
    De La Gándara Martín JJ; Sanz Granado O; Varona Martínez A; Such P
    Actas Esp Psiquiatr; 1999; 27(3):191-7. PubMed ID: 10431062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.
    Ravaris CL; Friedman MJ; Hauri PJ; McHugo GJ
    J Clin Psychopharmacol; 1991 Dec; 11(6):344-50. PubMed ID: 1770152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xanax XR for panic disorder.
    Med Lett Drugs Ther; 2003 May; 45(1157):43-4. PubMed ID: 12766702
    [No Abstract]   [Full Text] [Related]  

  • 12. Personality dimensions in panic disorder before and after effective treatment.
    Starcevic V; Uhlenhuth EH
    Anxiety; 1996; 2(2):95-8. PubMed ID: 9160608
    [No Abstract]   [Full Text] [Related]  

  • 13. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
    Lesser IM; Lydiard RB; Antal E; Rubin RT; Ballenger JC; DuPont R
    Am J Psychiatry; 1992 Nov; 149(11):1556-62. PubMed ID: 1415824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of alprazolam sublingual tablets in the treatment of the acute phase of panic disorders.
    Márquez M; Arenoso H; Caruso N
    Actas Esp Psiquiatr; 2011; 39(2):88-94. PubMed ID: 21404147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder.
    Schweizer E; Patterson W; Rickels K; Rosenthal M
    Am J Psychiatry; 1993 Aug; 150(8):1210-5. PubMed ID: 8328566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive style, alprazolam plasma levels, and treatment response in panic disorder.
    Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
    Depress Anxiety; 2008; 25(8):E18-26. PubMed ID: 17960759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alprazolam extended-release in panic disorder.
    Rickels K
    Expert Opin Pharmacother; 2004 Jul; 5(7):1599-611. PubMed ID: 15212610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diazepam versus alprazolam for the treatment of panic disorder.
    Noyes R; Burrows GD; Reich JH; Judd FK; Garvey MJ; Norman TR; Cook BL; Marriott P
    J Clin Psychiatry; 1996 Aug; 57(8):349-55. PubMed ID: 8752017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
    Greenblatt DJ; Harmatz JS; Shader RI
    Arch Gen Psychiatry; 1993 Sep; 50(9):715-22. PubMed ID: 8357297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpidem in the treatment of panic disorder.
    Schneier FR; Carrasco JL; Hollander E; Campeas R; Fallon B; Saoud JB; Feerick J; Liebowitz MR
    J Clin Psychopharmacol; 1993 Apr; 13(2):150-3. PubMed ID: 8096527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.